Outcomes of six-dose high-dose cytarabine (HiDAC-6) as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia (RR-AML).

被引：1
|
作者：
Veltri, Lauren Westfall [1 ]
Anders, Brandi [1 ]
Kanate, Abraham Sebastian [1 ]
Shillingburg, Alexandra [1 ]
Craig, Michael D. [1 ]
Cumpston, Aaron [1 ]
机构：
[1] West Virginia Univ, Morgantown, WV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e18508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18508
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients (Pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902.
    Stone, RM
    Moser, B
    Schulman, P
    Barrier, RC
    Kolitz, JE
    Allen, SL
    Stock, W
    Galinsky, IA
    Khoury, H
    Larson, RA
    BLOOD, 2004, 104 (11) : 249A - 249A
  • [2] Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)
    Ulf Schnetzke
    Peter Fix
    Baerbel Spies-Weisshart
    Karin Schrenk
    Anita Glaser
    Hans-Joerg Fricke
    Paul La Rosée
    Andreas Hochhaus
    Sebastian Scholl
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1391 - 1397
  • [3] Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)
    Schnetzke, Ulf
    Fix, Peter
    Spies-Weisshart, Baerbel
    Schrenk, Karin
    Glaser, Anita
    Fricke, Hans-Joerg
    La Rosee, Paul
    Hochhaus, Andreas
    Scholl, Sebastian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (08) : 1391 - 1397
  • [4] High dose cytarabine and cyclophosphamide (hAC) regimen for relapsed or refractory acute myeloid leukemia (AML): a retrospective monocentric analysis
    Fix, P.
    Fricke, H-J
    Spies-Weisshart, B.
    La Rosee, P.
    Hochhaus, A.
    Scholl, S.
    ONKOLOGIE, 2010, 33 : 138 - 139
  • [5] Safety and feasibility of outpatient high-dose cytarabine (HIDAC) and intermediate-dose cytarabine (IDAC) for consolidation therapy in acute myeloid leukemia (AML).
    Li, Wenhui
    Simondsen, Katherine
    Lee, Jamie
    Elharake, Maher
    Kubal, Timothy Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients
    Scappini, Barbara
    Gianfaldoni, Giacomo
    Caracciolo, Francesco
    Mannelli, Francesco
    Biagiotti, Caterina
    Romani, Claudio
    Pogliani, Enrico M.
    Simonetti, Federico
    Borin, Lorenza
    Fanci, Rosa
    Cutini, Ilaria
    Longo, Giovanni
    Susini, Maria Chiara
    Angelucci, Emanuele
    Bosi, Alberto
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) : 1047 - 1051
  • [7] Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy
    Advani, Anjali S.
    Gundacker, Holly
    Nyatanga, Nolyn
    Elson, Paul
    Rosen, Peter J.
    Bates, Jennifer
    Sekeres, Mikkael A.
    Kalaycio, Matt
    Sobecks, Ronald
    Copelan, Edward
    Appelbaum, Frederick R.
    BLOOD, 2011, 118 (21) : 1113 - 1113
  • [8] Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine
    Raanani, P
    Shpilberg, O
    Gillis, S
    Avigdor, A
    Hardan, I
    Berkowicz, M
    Sofer, O
    Lossos, I
    Chetrit, A
    Ben-Yehuda, D
    Bell-Bassat, I
    LEUKEMIA RESEARCH, 1999, 23 (08) : 695 - 700
  • [9] High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly
    Ahmed, Tamjeed
    Holwerda, Scott
    Pardee, Timothy
    Isom, Scott
    Lyerly, Susan
    Ellis, Leslie Renee
    Manuel, Megan
    Dralle, Sarah
    Dmitriy, Berenzon
    Klepin, Heidi D.
    Powell, Bayard L.
    BLOOD, 2013, 122 (21)
  • [10] High dose cytarabine, mitoxantrone and L-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly
    Ahmed, Tamjeed
    Holwerda, Scott
    Klepin, Heidi D.
    Isom, Scott
    Ellis, Leslie R.
    Lyerly, Susan
    Manuel, Megan
    Dralle, Sarah
    Berenzon, Dmitriy
    Powell, Bayard L.
    Pardee, Timothy S.
    LEUKEMIA RESEARCH, 2015, 39 (09) : 945 - 949
12345